Compare BXMT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | SUPN |
|---|---|---|
| Founded | 1966 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1998 | 2010 |
| Metric | BXMT | SUPN |
|---|---|---|
| Price | $18.18 | $44.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $21.38 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.2M | 571.0K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | ★ 154.70 | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | N/A | $22.70 |
| Revenue Next Year | N/A | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.67 | $31.16 |
| 52 Week High | $20.67 | $59.68 |
| Indicator | BXMT | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 42.48 |
| Support Level | $17.98 | $43.67 |
| Resistance Level | $18.89 | $46.79 |
| Average True Range (ATR) | 0.32 | 1.35 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 47.06 | 54.00 |
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.